# Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2

> **NCT04420611** · — · COMPLETED · sponsor: **Youssef Daali** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **OTHER:** Session 1 (day 1)
- **OTHER:** Session 2 (day 3)
- **OTHER:** Session 3 (day 15)
- **OTHER:** Session 4 (day 30)

## Key facts

- **NCT ID:** NCT04420611
- **Lead sponsor:** Youssef Daali
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420611, "Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04420611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*